共 163 条
- [1] Zolls S(2012)Particles in therapeutic protein formulations, Part 1: Overview of analytical methods J Pharm Sci 101 914-935
- [2] Tantipolphan R(2020)Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge Adv Drug Deliver Rev 167 66-77
- [3] Wiggenhorn M(2015)Subvisible (2–100 mu m) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis Biologicals 43 457-473
- [4] Winter G(2015)Subvisible (2–100 mu m) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy J Pharm Sci 104 1899-1908
- [5] Jiskoot W(2009)Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality J Pharm Sci 98 1201-1205
- [6] Friess W(2010)An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics J Pharm Sci 99 3302-3321
- [7] Hawe A(2021)Surfactant impact on interfacial protein aggregation and utilization of surface tension to predict surfactant requirements for biological formulations Mol Pharm 18 148-157
- [8] Sanchez-Felix M(2012)Issues and challenges of subvisible and submicron particulate analysis in protein solutions Aaps J 14 236-243
- [9] Burke M(2018)Deep convolutional neural network analysis of flow imaging microscopy data to classify subvisible particles in protein formulations J Pharm Sci 107 999-1008
- [10] Chen HH(2010)Characterization of particles in protein solutions: reaching the limits of current technologies Aaps J 12 708-715